PL418713A1 - Przeciwnowotworowe białko fuzyjne - Google Patents

Przeciwnowotworowe białko fuzyjne

Info

Publication number
PL418713A1
PL418713A1 PL418713A PL41871316A PL418713A1 PL 418713 A1 PL418713 A1 PL 418713A1 PL 418713 A PL418713 A PL 418713A PL 41871316 A PL41871316 A PL 41871316A PL 418713 A1 PL418713 A1 PL 418713A1
Authority
PL
Poland
Prior art keywords
antineoplastic
fusion protein
oncostatin
fragment
fusion proteins
Prior art date
Application number
PL418713A
Other languages
English (en)
Other versions
PL233352B1 (pl
Inventor
Sebastian Dominik Pawlak
Original Assignee
Adamed Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Spółka Z Ograniczoną Odpowiedzialnością filed Critical Adamed Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL418713A priority Critical patent/PL233352B1/pl
Priority to EP17777504.6A priority patent/EP3512562B1/en
Priority to PCT/EP2017/073245 priority patent/WO2018050808A1/en
Publication of PL418713A1 publication Critical patent/PL418713A1/pl
Publication of PL233352B1 publication Critical patent/PL233352B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Zgłoszenie dotyczy dziedziny terapeutycznych rekombinowanych białek fuzyjnych. Konkretnie, zgłoszenie dotyczy białek fuzyjnych egzotoksyny A Pseudomonas w połączeniu z fragmentem ludzkiej onkostatyny M (OSM) lub mutantem fragmentu onkostatyny M, mutanta fragmentu onkostatyny M oraz ich zastosowania w terapii przeciwnowotworowej.
PL418713A 2016-09-15 2016-09-15 Przeciwnowotworowe białko fuzyjne PL233352B1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL418713A PL233352B1 (pl) 2016-09-15 2016-09-15 Przeciwnowotworowe białko fuzyjne
EP17777504.6A EP3512562B1 (en) 2016-09-15 2017-09-15 Antineoplastic fusion protein
PCT/EP2017/073245 WO2018050808A1 (en) 2016-09-15 2017-09-15 Antineoplastic fusion protein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL418713A PL233352B1 (pl) 2016-09-15 2016-09-15 Przeciwnowotworowe białko fuzyjne

Publications (2)

Publication Number Publication Date
PL418713A1 true PL418713A1 (pl) 2018-03-26
PL233352B1 PL233352B1 (pl) 2019-10-31

Family

ID=59997318

Family Applications (1)

Application Number Title Priority Date Filing Date
PL418713A PL233352B1 (pl) 2016-09-15 2016-09-15 Przeciwnowotworowe białko fuzyjne

Country Status (3)

Country Link
EP (1) EP3512562B1 (pl)
PL (1) PL233352B1 (pl)
WO (1) WO2018050808A1 (pl)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
PL397167A1 (pl) * 2011-11-28 2013-06-10 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
WO2013178783A1 (en) * 2012-06-01 2013-12-05 Ablynx N.V. P2x7 receptor antagonists and agonists
KR20250058773A (ko) * 2015-09-11 2025-04-30 바이오셉터 (어스트) 피티와이 엘티디 키메라 항원 수용체 및 이의 용도
WO2017193059A1 (en) * 2016-05-06 2017-11-09 The Regents Of The University Of California Systems and methods for targeting cancer cells

Also Published As

Publication number Publication date
PL233352B1 (pl) 2019-10-31
WO2018050808A1 (en) 2018-03-22
EP3512562B1 (en) 2021-06-30
EP3512562A1 (en) 2019-07-24

Similar Documents

Publication Publication Date Title
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
CY1124153T1 (el) Αντισωματα και πολυπεπτιδια που κατευθυνονται εναντι cd127
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
MX393740B (es) Anticuerpos contra alfa-sinucleina y sus usos.
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
IL275779A (en) Recombinant human sialidases, sialidase-related proteins and methods of using them
LT3849614T (lt) Interleukino-2 polipeptido konjugatai ir jų panaudojimas
MX2025000260A (es) Proteina de union al antigeno anti-steap1
MX2020004807A (es) Agentes radioterapeuticos y de imagenologia que se dirigen a proteina-alfa de activacion fibroblastos (fap-alfa).
CL2017003261A1 (es) Factor xi anticuerpos y métodos de uso
MA43859A (fr) Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion
BR112015020911A2 (pt) anticorpo, uso de uma combinação e método de tratamento
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
MX2018013762A (es) Polipeptidos de fusion de ligando de cumulo de diferenciacion 40 y fragmento cristalizable (cd40l-fc) y sus metodos de uso.
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
EP4349864A3 (en) Oncostatin m receptor antigen binding proteins
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
MX389320B (es) Anticuerpos anti-tnfrsf25
ZA202000595B (en) Novel therapeutic enzyme fusion protein and use thereof
JOP20200329A1 (ar) بروتينات وشظايا سائدة مناعيا في التصلب المتعدد
PE20170287A1 (es) Anticuerpos anti-proteina similar a angiopoyetina 4 y metodos de uso
MX2019011196A (es) Neurotoxinas botulinas para uso en terapia.